| Withdrawn | Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gyn NCT07226102 | City of Hope Medical Center | N/A |
| Suspended | Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer NCT07136493 | City of Hope Medical Center | N/A |
| Recruiting | Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC NCT07016399 | Vandana Abramson | Phase 2 |
| Recruiting | Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Bre NCT06635980 | Mayo Clinic | Phase 2 |
| Recruiting | Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast C NCT06582615 | Ohio State University Comprehensive Cancer Center | N/A |
| Recruiting | Access to Genetic Testing in Underserved Patients With Cancer NCT06422455 | University of Southern California | N/A |
| Recruiting | Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cance NCT05677802 | Ohio State University Comprehensive Cancer Center | N/A |
| Active Not Recruiting | STEMVAC in Patients With Early Stage Triple Negative Breast Cancer NCT05455658 | University of Washington | Phase 2 |
| Terminated | Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy NCT04835597 | M.D. Anderson Cancer Center | — |
| Suspended | Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic NCT05111561 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Withdrawn | Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV T NCT05177796 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer NCT05086731 | Emory University | N/A |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or C NCT04491942 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer NCT04959474 | Thomas Jefferson University | N/A |
| Completed | Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer NCT05071677 | M.D. Anderson Cancer Center | — |
| Completed | Nipple Aspirate Fluid in Detecting Breast Cancer NCT03715959 | Ohio State University Comprehensive Cancer Center | N/A |
| Active Not Recruiting | National Cancer Institute "Cancer Moonshot Biobank" NCT04314401 | National Cancer Institute (NCI) | — |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemo NCT04052555 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | RBX7455 Before Surgery for the Treatment of Operable Breast Cancer NCT04139993 | Mayo Clinic | Phase 1 |
| Terminated | Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With NCT04216472 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Ca NCT03979508 | Mayo Clinic | Phase 2 |
| Completed | Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple NCT04081389 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Patho NCT03872388 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patie NCT03199040 | Washington University School of Medicine | Phase 1 |
| Terminated | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Tr NCT04185311 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectabl NCT03971409 | Laura Huppert, MD, BA | Phase 2 |
| Completed | Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Can NCT03207529 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutati NCT03218826 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer NCT03544125 | OHSU Knight Cancer Institute | Phase 1 |
| Withdrawn | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors Th NCT03326258 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast C NCT03012230 | Mayo Clinic | Phase 1 |
| Completed | A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) NCT03232593 | Hoffmann-La Roche | — |
| Completed | IACS-010759 in Advanced Cancers NCT03291938 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Can NCT03213041 | Northwestern University | Phase 2 |
| Completed | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer NCT03154190 | Stanford University | N/A |
| Active Not Recruiting | Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnos NCT02883062 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer NCT03106077 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hor NCT03044730 | Northwestern University | Phase 2 |
| Suspended | Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) NCT02993068 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Tr NCT03012100 | Academic and Community Cancer Research United | Phase 2 |
| Completed | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent O NCT02996825 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca NCT02957968 | Virginia Commonwealth University | Phase 2 |
| Recruiting | Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuva NCT02945579 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer NCT02954874 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer NCT02744053 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Completed | Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC NCT02593175 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Brea NCT02876107 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Tr NCT02689427 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors NCT02498613 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy NCT02432963 | City of Hope Medical Center | Phase 1 |
| Withdrawn | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery an NCT02567396 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative NCT02648477 | City of Hope Medical Center | Phase 2 |
| Completed | Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negat NCT02672475 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Withdrawn | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent NCT02627430 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer NCT02530489 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer NCT02474173 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicte NCT02456857 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer NCT02276443 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy NCT02445391 | ECOG-ACRIN Cancer Research Group | Phase 3 |
| Active Not Recruiting | Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating NCT02488967 | NRG Oncology | Phase 3 |
| Completed | 18F-FSPG PET/CT for Cancer Patients on Therapy NCT02599194 | Andrei Iagaru | Phase 2 |
| Terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherap NCT02419495 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple- NCT02411656 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Bre NCT02457910 | Vanderbilt-Ingram Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian NCT02208375 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer NCT02120469 | City of Hope Medical Center | Phase 1 |
| Terminated | Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiv NCT01957514 | University of Washington | — |
| Completed | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer NCT01964924 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck C NCT01846091 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Brea NCT01750073 | University of Nebraska | Phase 2 |
| Completed | Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer NCT01624441 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer NCT01575522 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer NCT01349959 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer NCT01319539 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metasta NCT01281150 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Tr NCT01238133 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Remo NCT01276496 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer NCT01251874 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer NCT01145430 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Canc NCT01116648 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Su NCT01071564 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Trea NCT00861705 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy NCT00892736 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Remove NCT00576654 | National Cancer Institute (NCI) | Phase 1 |